Other

Dataset Information

1K

PATERSON INSTITUTE FOR CANCER RESEARCH

ABSTRACT: Organisation EGAO00000000039

PROVIDER: EGAO00000000039 | EGA |

REPOSITORIES: EGA

Json Xml
altmetric image

Publications

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.

Korfi K K   Mandal A A   Furney S J SJ   Wiseman D D   Somervaille T C P TCP   Marais R R  

Annals of oncology : official journal of the European Society for Medical Oncology 20150223 6

<h4>Background</h4>Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T315I mutation in the kinase domain of BCR-ABL1 confers resistance to all clinically approved TKIs, except ponatinib. However, compound mutations can mediate resistance even to ponatinib and rem  ...[more]

Similar Datasets

Other INSTITUTE OF CANCER RESEARCH
| EGAO00000000038 | EGA
Other,Multiomics The Cancer Research UK Cambridge Research Institute
| EGAO00000000060 | EGA
Other Children's Cancer Research Institute, Vienna
| EGAO00000000355 | EGA
Other The Institute of Cancer Research
| EGAO00000000404 | EGA
Other Ontario Institute for Cancer Research
| EGAO00000001145 | EGA
Other Institute of Cancer Research, London
| EGAO00000000254 | EGA
Other Ontario Institute of Cancer Research
| EGAO00000000906 | EGA
Transcriptomics The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel
2013-02-01 | E-MTAB-1496 | biostudies-arrayexpress
Other The Institute of Cancer Research, London
| EGAO00000000318 | EGA
Other Institute of Cancer Research, London, UK
| EGAO00000000478 | EGA